SEC Form 4 · accession 0000899243-19-000497
ALPINE IMMUNE SCIENCES, INC. · ALPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter A. Thompson
Director · 10% Owner
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626199
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F3,F1,F2 | $4.09 | Jan 2, 2019 | A | 7,650 | A | — | Jan 1, 2029 | Common Stock | 7,650 | 7,650 | D |
Explanation of responses
- F1The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
- F21/12th of the shares subject to the option become vested and exercisable on February 2, 2019 and 1/12th of the shares subject to the option shall vest monthly thereafter.
- F3In accordance with the internal policies of OrbiMed Advisors LLC, the options received by Dr. Thompson must be held for the benefit of OrbiMed Advisors LLC and its affiliates.